What the FDA labels say about taking them together
Rifampin and ticagrelor
Ticagrelor's FDA label of May 7, 2026 names rifampin in its drug interactions section; the rifampin label PlainMeds reads does not name ticagrelor. The ticagrelor label: “Avoid use with strong inducers of CYP3A.”
Check it at the source: the rifampin FDA label on DailyMed (effective February 11, 2026, Lupin Pharmaceuticals, Inc.); the ticagrelor FDA label on DailyMed (effective May 7, 2026, AstraZeneca Pharmaceuticals LP).
What does the rifampin label say about ticagrelor?
Rifampin's label (effective February 11, 2026) does not name ticagrelor in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (rifampin), Lupin Pharmaceuticals, Inc., effective February 11, 2026 (SPL set b56004f0-f23d-47f6-80c7-39884fccbccc), via openFDA; the full label on DailyMed
What does the ticagrelor label say about rifampin?
Ticagrelor label, drug interactionsAvoid use with strong inducers of CYP3A (e.g., rifampin, phenytoin, carbamazepine and phenobarbital) [see Clinical Pharmacology (12.3) ].
Source: FDA drug label (BRILINTA), AstraZeneca Pharmaceuticals LP, effective May 7, 2026 (SPL set f7b3f443-e83d-4bf2-0e96-023448fed9a8), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Rifampin | Ticagrelor | |
|---|---|---|
| Labeled for | n/a | Heart attack and coronary artery disease, Stroke prevention |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $0.679 per capsule 300 mg capsule | $0.253 per tablet 90 mg tablet |
| Shortage now | In shortage | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once